{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:02:23Z","timestamp":1773680543366,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T00:00:00Z","timestamp":1421280000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1010-x","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T15:10:54Z","timestamp":1421248254000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Molecular characteristics of endometrial cancer coexisting with peritoneal malignant mesothelioma in Li-Fraumeni-like syndrome"],"prefix":"10.1186","volume":"15","author":[{"given":"Angel","family":"Chao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chyong-Huey","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Shien","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shir-Hwa","family":"Ueng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiao-Yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,15]]},"reference":[{"key":"1010_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/B978-0-323-07419-3.00005-9","volume-title":"Clinical gynecologic oncology","author":"WT Creasman","year":"2012","unstructured":"Creasman WT, Miller DS. Adenocarcinoma of the Uterine Corpus. In: Di Saia PJ, Creasman WT, editors. Clinical gynecologic oncology. Philadelphia: Elsevier; 2012. p. 141\u201374."},{"issue":"3","key":"1010_CR2","first-page":"394","volume":"25","author":"S Erkanli","year":"2004","unstructured":"Erkanli S, Kilicdag EB, Bolat F, Kayaselcuk F, Bagis T, Haberal A, et al. Well-differentiated papillary mesothelioma complicating endometrial carcinoma: a case report. Eur J Gynaecol Oncol. 2004;25(3):394\u20136.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"2","key":"1010_CR3","first-page":"200","volume":"27","author":"C Baykal","year":"2006","unstructured":"Baykal C, Arioglu P, Gultekin M, Usubutun A, Ficicioglu C, Ayhan A. Well differentiated mesothelioma complicating endometrial carcinoma; a case report. Eur J Gynaecol Oncol. 2006;27(2):200.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"5 Suppl","key":"1010_CR4","first-page":"793","volume":"54","author":"V Rathi","year":"2010","unstructured":"Rathi V, Hyde S, Newman M. Well-differentiated papillary mesothelioma in association with endometrial carcinoma: a case report. Acta Cytol. 2010;54(5 Suppl):793\u20137.","journal-title":"Acta Cytol"},{"issue":"7447","key":"1010_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67\u201373.","journal-title":"Nature"},{"issue":"3","key":"1010_CR6","first-page":"745","volume":"56","author":"RL Bennett","year":"1995","unstructured":"Bennett RL, Steinhaus KA, Uhrich SB, O\u2019Sullivan CK, Resta RG, Lochner-Doyle D, et al. Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. Am J Hum Genet. 1995;56(3):745\u201352.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1010_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ctrv.2011.10.006","volume":"38","author":"P Mirarabshahii","year":"2012","unstructured":"Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma\u2013an update on treatment. Cancer Treat Rev. 2012;38(6):605\u201312.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1010_CR8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ygyno.2013.02.032","volume":"129","author":"A Chao","year":"2013","unstructured":"Chao A, Tang YH, Lai CH, Chang CJ, Chang SC, Wu TI, et al. Potential of an age-stratified CA125 cut-off value to improve the prognostic classification of patients with endometrial cancer. Gynecol Oncol. 2013;129(3):500\u20134.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1010_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.lungcan.2013.07.011","volume":"82","author":"AJ Hubers","year":"2013","unstructured":"Hubers AJ, Heideman DA, Yatabe Y, Wood MD, Tull J, Taron M, et al. EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study. Lung Cancer. 2013;82(1):38\u201343.","journal-title":"Lung Cancer"},{"key":"1010_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1755-8794-2-8","volume":"2","author":"Y Wang","year":"2009","unstructured":"Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, Moorhead M, et al. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics. 2009;2:8.","journal-title":"BMC Med Genomics"},{"issue":"3","key":"1010_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1158\/1535-7163.MCT-10-0994","volume":"10","author":"F Janku","year":"2011","unstructured":"Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors. Mol Cancer Ther. 2011;10(3):558\u201365.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1010_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1517\/14656566.2013.770475","volume":"14","author":"AK Salama","year":"2013","unstructured":"Salama AK, Kim KB. Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother. 2013;14(5):619\u201327.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"1010_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/humu.10185","volume":"21","author":"JM Varley","year":"2003","unstructured":"Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat. 2003;21(3):313\u201320.","journal-title":"Hum Mutat"},{"issue":"6","key":"1010_CR14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/sj.cdd.4401913","volume":"13","author":"JA Royds","year":"2006","unstructured":"Royds JA, Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ. 2006;13(6):1017\u201326.","journal-title":"Cell Death Differ"},{"issue":"2","key":"1010_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrc2584","volume":"9","author":"C Whibley","year":"2009","unstructured":"Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95\u2013107.","journal-title":"Nat Rev Cancer"},{"issue":"9174","key":"1010_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(99)01914-5","volume":"354","author":"I Zehbe","year":"1999","unstructured":"Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet. 1999;354(9174):218\u20139.","journal-title":"Lancet"},{"issue":"7","key":"1010_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1368-8375(00)00139-1","volume":"37","author":"G Sourvinos","year":"2001","unstructured":"Sourvinos G, Rizos E, Spandidos DA. p53 Codon 72 polymorphism is linked to the development and not the progression of benign and malignant laryngeal tumours. Oral Oncol. 2001;37(7):572\u20138.","journal-title":"Oral Oncol"},{"issue":"1","key":"1010_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cancergencyto.2003.07.010","volume":"150","author":"SS Cortezzi","year":"2004","unstructured":"Cortezzi SS, Provazzi PJ, Sobrinho JS, Mann-Prado JC, Reis PM, de Freitas SE, et al. Analysis of human papillomavirus prevalence and TP53 polymorphism in head and neck squamous cell carcinomas. Cancer Genet Cytogenet. 2004;150(1):44\u20139.","journal-title":"Cancer Genet Cytogenet"},{"issue":"10","key":"1010_CR19","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/carcin\/bgi125","volume":"26","author":"HH Nelson","year":"2005","unstructured":"Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis. 2005;26(10):1770\u20133.","journal-title":"Carcinogenesis"},{"issue":"2","key":"1010_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0304-3835(01)00867-9","volume":"179","author":"N Soulitzis","year":"2002","unstructured":"Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 2002;179(2):175\u201383.","journal-title":"Cancer Lett"},{"issue":"8","key":"1010_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/jnci\/90.8.606","volume":"90","author":"M Hisada","year":"1998","unstructured":"Hisada M, Garber JE, Fung CY, Fraumeni Jr JF, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90(8):606\u201311.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1010_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nrclinonc.2014.41","volume":"11","author":"KA McBride","year":"2014","unstructured":"McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol. 2014;11(5):260\u201371.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1010-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1010-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1010-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1010-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T07:23:43Z","timestamp":1630567423000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1010-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,15]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1010"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1010-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,15]]},"assertion":[{"value":"5 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"8"}}